New class of antigen-specific cancer immunotherapy
based on an off-the-shelf antigen presenting cell line

News

PDC*LINE PHARMA IS HIRING! WE HAVE AN OPEN POSITION FOR A RESEARCH ENGINEER – HUMAN IMMUNOLOGY.

2020-05

PDC*line Pharma is hiring! We have an open position for a Senior/Principal Scientist. Are you interested to join an international dynamic team in the biotech cancer vaccine space? Be part of the adventure and join us!

In order to strengthen the team

Read more about PDC*LINE PHARMA IS HIRING! WE HAVE AN OPEN POSITION FOR A RESEARCH ENGINEER – HUMAN IMMUNOLOGY.

Publication in OncoImmunology of the results of the first in-human trial with our PDC*line vaccine in melanoma

2020-04

We are very pleased to announce the publication in OncoImmunology of the results of the first in-human trial with our innovative plasmacytoid dendritic cell line based cancer vaccine in melanoma (April 12th 2020).

Abstract

The efficacy of immune

Read more about Publication in OncoImmunology of the results of the first in-human trial with our PDC*line vaccine in melanoma

Interview of our President & CEO published in the magazine PharmaBoardroom

2020-04

New article and interview of our President & CEO Eric Halioua for the 2020 edition of the Belgium Healthcare & Life Science Review of the magazine PharmaBoardroom. He introduces the Belgian immuno-onco biotech, our clinical-stage assets, the impact

Read more about Interview of our President & CEO published in the magazine PharmaBoardroom

PDCline Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate (PDClung01) targeting non-small cell lung cancer

2020-03

Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its

Read more about PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate (PDC*lung01) targeting non-small cell lung cancer

PDC*line Pharma raises €20 million ($22.2M) in Series B financing round

2020-01

Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of

Read more about PDC*line Pharma raises €20 million ($22.2M) in Series B financing round

linkedin twitter

PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in early clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).

About us

A first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages

Potent & effective

Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

Scalable & convenient

Simple production of a large quantity of a highly qualified off-the-shelf product

Versatile & applicable to any cancers

The peptides can easily be changed to target a specific cancer type

Management Team

Candidate products

Melanoma

Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

Melanoma is often easier to detect in its early stages than most cancers. However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Despite new treatments, prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

Read more about PDC mel

Lung Cancer

Lung cancer is the most common malignancy worldwide for male patients and for both sexes combined (2.1 million new cases per year), and the third most common for female patients (after breast and colorectal cancers). Deaths from lung cancer exceed those from any other malignancy globally, with the number of lung-cancer-related deaths worldwide for 2018 estimated at 1.8 million (Globocan 2018), representing 18.4% for both sexes. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

Read more about Lung Cancer

Technology

PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.

About our technology